Ocuphire Pharma, Inc. (REXN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Aquestive Therapeutics, Inc.

SCYNEXIS, Inc.

FibroGen, Inc.

CytomX Therapeutics, Inc.

Ocuphire Pharma, Inc.

Capricor Therapeutics, Inc.

Chimerix, Inc.

Achieve Life Sciences, Inc.

Annovis Bio, Inc.

aTyr Pharma, Inc.

Anebulo Pharmaceuticals, Inc.

Why is Ocuphire Pharma, Inc. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -9.05

The company has declared negative results for the last 3 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -38.99 MM
DEBT-EQUITY RATIO (HY) Highest at 74.23 %
NET SALES(Q) Lowest at USD 2.16 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 337.02%, its profits have fallen by -28.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ocuphire Pharma, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Ocuphire Pharma, Inc.

337.02%

1.88

74.27%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

65.32%

EBIT Growth (5y)

-231.97%

EBIT to Interest (avg)

-9.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-4.52

Sales to Capital Employed (avg)

0.74

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.53%

ROCE (avg)

166.10%

ROE (avg)

9.08%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

20.17

EV to EBIT

-6.88

EV to EBITDA

-6.89

EV to Capital Employed

-9.28

EV to Sales

18.70

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-248.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at USD -24.98 MM

ROCE(HY)

Highest at 0%

RAW MATERIAL COST(Y)

Fallen by 0.3% (YoY

-31What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -38.99 MM

DEBT-EQUITY RATIO (HY)

Highest at 74.23 %

NET SALES(Q)

Lowest at USD 2.16 MM

OPERATING PROFIT(Q)

Lowest at USD -14.35 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -665.32 %

PRE-TAX PROFIT(Q)

Lowest at USD -14.17 MM

NET PROFIT(Q)

Lowest at USD -14.17 MM

EPS(Q)

Lowest at USD -0.75

Here's what is working for Ocuphire Pharma, Inc.

Raw Material Cost

Fallen by 0.3% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ocuphire Pharma, Inc.

Net Sales

At USD 2.16 MM has Fallen at -39.22%

over average net sales of the previous four periods of USD 3.55 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -14.17 MM has Fallen at -48.88%

over average net sales of the previous four periods of USD -9.52 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -14.17 MM has Fallen at -48.88%

over average net sales of the previous four periods of USD -9.52 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -38.99 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Sales

Lowest at USD 2.16 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -14.35 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -665.32 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -14.17 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -14.17 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.75

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Highest at 74.23 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio